These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24706516)

  • 1. Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment.
    Song S; Kang D; Halim AB; Miller R
    J Clin Pharmacol; 2014 Aug; 54(8):910-6. PubMed ID: 24706516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.
    Yin OQP; Antman EM; Braunwald E; Mercuri MF; Miller R; Morrow D; Ruff CT; Truitt K; Weitz JI; Giugliano RP
    Circulation; 2018 Oct; 138(18):1963-1973. PubMed ID: 29967197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
    Goto E; Horinaka S; Ishimitsu T; Kato T
    Drug Metab Pharmacokinet; 2020 Feb; 35(1):151-159. PubMed ID: 32007354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.
    Lu G; Pine P; Leeds JM; DeGuzman F; Pratikhya P; Lin J; Malinowski J; Hollenbach SJ; Curnutte JT; Conley PB
    PLoS One; 2018; 13(3):e0195122. PubMed ID: 29590221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
    Mendell J; Lee F; Chen S; Worland V; Shi M; Samama MM
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):212-21. PubMed ID: 23615159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
    Salazar DE; Mendell J; Kastrissios H; Green M; Carrothers TJ; Song S; Patel I; Bocanegra TS; Antman EM; Giugliano RP; Kunitada S; Dornseif B; Shi M; Tachibana M; Zhou S; Rohatagi S
    Thromb Haemost; 2012 May; 107(5):925-36. PubMed ID: 22398655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Edoxaban: Review of pharmacology and key phase I to III clinical trials.
    Plitt A; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Sep; 19(5):409-16. PubMed ID: 24607764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
    Hillarp A; Strandberg K; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Lindahl TL
    Scand J Clin Lab Invest; 2018; 78(7-8):575-583. PubMed ID: 30278787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure.
    Aspromonte N; Colivicchi F
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):113-122. PubMed ID: 27819149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
    Honda Y; Kamisato C; Morishima Y
    Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study.
    Jönsson S; Simonsson US; Miller R; Karlsson MO
    J Clin Pharmacol; 2015 Nov; 55(11):1268-79. PubMed ID: 25966665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay.
    He L; Kochan J; Lin M; Vandell A; Brown K; Depasse F
    Thromb Res; 2017 Jul; 155():121-127. PubMed ID: 28535438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.
    Girgis IG; Patel MR; Peters GR; Moore KT; Mahaffey KW; Nessel CC; Halperin JL; Califf RM; Fox KA; Becker RC
    J Clin Pharmacol; 2014 Aug; 54(8):917-27. PubMed ID: 24668660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Edoxaban: a focused review of its clinical pharmacology.
    Lip GY; Agnelli G
    Eur Heart J; 2014 Jul; 35(28):1844-55. PubMed ID: 24810388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination.
    Mendell J; Noveck RJ; Shi M
    J Cardiovasc Pharmacol; 2012 Oct; 60(4):335-41. PubMed ID: 23064240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.
    Barrios V; Escobar C
    Expert Rev Cardiovasc Ther; 2015; 13(7):811-24. PubMed ID: 26068539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edoxaban tosylate.
    Am J Cardiovasc Drugs; 2011; 11(2):129-35. PubMed ID: 21446778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.
    Rohatagi S; Mendell J; Kastrissios H; Green M; Shi M; Patel I; Salazar DE
    Thromb Haemost; 2012 Nov; 108(5):887-95. PubMed ID: 23014669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
    Morishima Y; Kamisato C; Honda Y
    Eur J Pharmacol; 2014 Nov; 742():15-21. PubMed ID: 25179572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.